Quintiles, which recently went private and has been looking to reduce debt, is selling its Bioglan Pharmaceuticals subsidiary.

Quintiles gets $183 million in cash plus the costs for products in inventory from Bradley Pharmaceuticals, which is based in New Jersey.

The Triangle Business Journal reported that Quintiles acquired Bioglan for $53.7 million.

Bioglan developed dermatology products.

Quintiles: www.quintiles.com